BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36259380)

  • 1. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
    Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
    Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
    Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 4. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
    Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
    JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
    Lin YS; Zhang X; Wang C; Liu YQ; Guan WM; Liang J
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3027-e3036. PubMed ID: 33769497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer.
    Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
    Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Duke ES; Barone AK; Chatterjee S; Mishra-Kalyani PS; Shen YL; Isikwei E; Zhao H; Bi Y; Liu J; Rahman NA; Wearne E; Leighton JK; Stephenson M; Ojofeitimi I; Scepura B; Nair A; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Oct; 28(19):4173-4177. PubMed ID: 35679021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
    Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
    Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
    Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
    Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
    Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
    Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
    N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
    J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
    Capdevila J; Klochikhin A; Leboulleux S; Isaev P; Badiu C; Robinson B; Hughes BGM; Keam B; Parnis F; Elisei R; Gajate P; Gan HK; Kapiteijn E; Locati L; Mangeshkar M; Faoro L; Krajewska J; Jarzab B
    Thyroid; 2022 May; 32(5):515-524. PubMed ID: 35403447
    [No Abstract]   [Full Text] [Related]  

  • 18. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
    Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M
    Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.
    Du W; Shi X; Fang Q; Zhang X; Liu S
    Front Endocrinol (Lausanne); 2022; 13():768028. PubMed ID: 35282451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
    BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.